Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems [clinicaltrials:NCT00006066]
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems [clinicaltrials:NCT00006066]
Bio2RDF identifier
NCT00006066
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00006066
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... what doses are safe to give.
brief title [clinicaltrials_vocabulary:brief-title]
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2006-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
One of the challenges i ...... ine antibody
responses.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-07-14T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Anti-HIV Agents
CD4 Lymphocyte Count
Dose-Response Relationship, Drug
Drug Therapy, Combination
Immunocompromised Host
Injections, Subcutaneous
Interleukin-2
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-05-17T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00006066
official title [clinicaltrials_vocabulary:official-title]
Phase I/II Trial of Subcutaneo ...... hildren With Immunosuppression
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-05-01T00:00:00Z
identifier
clinicaltrials:NCT00006066
title
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
@en
type
label
Interleukin-2 Plus Anti-HIV Th ...... s [clinicaltrials:NCT00006066]
@en